GlassScriptPhysician profile
Kavan Ramachandran
NPI 1972799252
$2,576.31
in general payments reported to CMS, 2019-2025
24 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $772 · 2020: $375 · 2021: $283 · 2022: $278 · 2023: $580 · 2024: $169 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $852 · Education: $16.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $852.01 |
| Education | $16.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $437.86 | 2019-2023 | Nucala |
| Astrazeneca Pharmaceuticals LP | $334.79 | 2019-2023 | Fasenra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.57 | 2019-2025 | Ofev |
| Actelion Pharmaceuticals US, INC. | $237.80 | 2019-2023 | Opsumit, Uptravi |
| Grifols USA, LLC | $158.31 | 2019-2024 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $117.74 | 2023-2024 | Verquvo, Zerbaxa, Recarbrio |
| Novartis Pharmaceuticals Corporation | $114.21 | 2019-2023 | |
| Genentech USA, INC. | $112.36 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $105.55 | 2019-2020 | |
| Genzyme Corporation | $95.03 | 2019-2023 | |
| Mylan Specialty L.P. | $84.04 | 2019-2023 | Yupelri |
| Insmed, INC. | $73.84 | 2023-2024 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $64.53 | 2019-2022 | |
| United Therapeutics Corporation | $59.86 | 2021-2024 | Tyvaso |
| Amgen INC. | $58.33 | 2023 | Tezspire |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $45.76 | 2019-2020 | |
| Harmony Biosciences LLC | $43.41 | 2023 | Wakix |
| Takeda Pharmaceuticals U.S.A., INC. | $36.25 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $34.72 | 2023 | Xywav |
| Gilead Sciences, INC. | $29.63 | 2021-2023 | Veklury |
| Mallinckrodt Enterprises LLC | $23.57 | 2019 | |
| Electromed, INC. | $18.03 | 2023 | Smartvest |
| Allergan, INC. | $10.96 | 2019 | |
| Veran Medical Technologies, INC. | $8.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kavan Ramachandran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.